Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
Parisa MomtazCatherine A O'ConnorJoanne F ChouMarinela CapanuWungki ParkChaitanya BandlamudiMichael F BergerDavid P KelsenSarah P SuehnholzDebyani ChakravartyKenneth H YuAnna M VargheseAlice ZervoudakisJia LiGeoffrey Y KuJennifer S ParkMarina ShcherbaJames J HardingZoe GoldbergGhassan K Abou-AlfaErin E Salo-MullenZsofia K StadlerChristine A Iacobuzio-DonahueEileen M O'ReillyPublished in: Cancer (2021)
g/sBRCA1/2 mutations did not appear to have different actionable utility. Platinum and PARPi therapies offer therapeutic benefit, and very durable outcomes are observed in a subset of patients who have g/sBRCA1/2 mutations with biallelic status.